CLCS (Cell Source) YoY EBITDA Growth: 80.77% (As of Dec. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLCS Cell Source Inc CLCS
35 GF Score
Price $0.86
View Full Analysis

What is Cell Source YoY EBITDA Growth?

Cell Source CLCS 35 YoY EBITDA Growth is 80.77% as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cell Source's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was 80.77%.

Cell Source's EBITDA per Share for the three months ended in Dec. 2024 was $-0.01.

Cell Source YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cell Source's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source YoY EBITDA Growth Chart

Cell Source Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.97 0.80 3.23 5.83 27.43

Cell Source Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.33 26.32 -26.09 19.23 80.77
CLCS
35GF Score
Cell Source Inc CLCS
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cell Source YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cell Source's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.082--0.113)/ | -0.113 |
=27.43 %

Cell Source's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (Q: Dec. 2024 )
=(EBITDA per Share (Q: Dec. 2024 )-EBITDA per Share (Q: Dec. 2023 )) / | EBITDA per Share (Q: Dec. 2023 )) |
=(-0.005--0.026)/ | -0.026 |
=80.77 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 80.77% mean?
Cell Source (CLCS) has a YoY EBITDA Growth of 80.77% as of Dec. 2024. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cell Source and its competitors.
Is Cell Source's YoY EBITDA Growth too high?
Cell Source's current YoY EBITDA Growth is 80.77%. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Cell Source's YoY EBITDA Growth compare to EDSA and CTXR?
Cell Source's YoY EBITDA Growth of 80.77% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cell Source and its competitors. Cell Source's current YoY EBITDA Growth is 80.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Source stock overvalued right now?
Cell Source (CLCS) has a current YoY EBITDA Growth of 80.77%. The current YoY EBITDA Growth is 80.77%. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cell Source (CLCS), the current YoY EBITDA Growth is 80.77% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019
Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.
35GF Score

Get the complete analysis for CLCS

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.86
Price